• Case Studies in Preventing Medication Errors in People with HIV and Comorbidities

  • Assessment

    Please answer the following questions based on what you learned in this activity.
  • 1. Which of the following resources is most applicable to use for an all-in-one immediate interaction check between bictegravir/tenofovir alafenamide/emtricitabine and various primary care medications?*

  • Congratulations. The correct answer is C. While options B and D will give general information as to likelihood of antiretroviral interactions, only option C will give a comprehensive, searchable database allowing to check multiple agents at once. Option A is incorrect as the national clinician consultation center will provide drug-interaction expertise, though a response may or may not be immediate.

    Reference: University of Liverpool (hiv-druginteractions.org)

     

  • Sorry, the correct answer is C. While options B and D will give general information as to likelihood of antiretroviral interactions, only option C will give a comprehensive, searchable database allowing to check multiple agents at once. Option A is incorrect as the national clinician consultation center will provide drug-interaction expertise, though a response may or may not be immediate.

    Reference: University of Liverpool (hiv-druginteractions.org)

  • 2. Which of the following HIV medications can have its absorption impacted by daily oral omeprazole?*

  • Congratulations. The correct answer is C. Oral rilpivirine. Rilpivirine should not be co-administered with omeprazole as it leads to a significant decreases in rilpivirine plasma concentrations due to an increase in gastric pH. Intramuscular concentrations of rilpivirine will not be affected by coadministration with omeprazole.

    Reference: Package insert. Availablle at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fb109de9-d88d-4405-8dd6-d458cbc387d1&type=display 

     

     

  • Sorry, the correct answer is C. Oral rilpivirine. Rilpivirine should not be co-administered with omeprazole as it leads to a significant decreases in rilpivirine plasma concentrations due to an increase in gastric pH. Intramuscular concentrations of rilpivirine will not be affected by coadministration with omeprazole.

    Reference: Package insert. Availablle at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fb109de9-d88d-4405-8dd6-d458cbc387d1&type=display 



  • 3. JD is currently taking dolutegravir/lamivudine by mouth once daily for his HIV treatment. His partner wants him to start taking a number of over the counter supplements. Which of the following supplements, if taken incorrectly, could potentially impact the efficacy of his HIV treatment?*

  • Congratulations. The correct answer is B. Magnesium. Magnesium is a polyvalent cation that can bind to and inactive several integrase inhibitors like dolutegravir. Dolutegravir should be administered 2 hours before or 6 hours after taking medications containing polyvalent cations. The other three supplement have no concerns with the antiretroviral therapy.

    Reference: Package insert. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e45422-43ed-4cfb-9356-fae88d14a53a 

  • Sorry, the correct answer is B. Magnesium. Magnesium is a polyvalent cation that can bind to and inactive several integrase inhibitors like dolutegravir. Dolutegravir should be administered 2 hours before or 6 hours after taking medications containing polyvalent cations. The other three supplement have no concerns with the antiretroviral therapy.

    Reference: Package insert. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e45422-43ed-4cfb-9356-fae88d14a53a 

  • EVALUATION

    To receive your CME/CE credit for participating in this activity, please complete the following evaluation.
  • After participating in the webinar, please rate your current confidence in preventing medication errors in people with HIV and comorbidities.
  • Did your confidence improve?
  • Please rate your agreement with the following statements.*
    Rows
  • Please rate your agreement with the following statements.*
    Rows
  • Please indicate your agreement with the following statements about barriers to making changes.*
    Rows
  • What specific barrier(s) impact your ability to make the change(s) you indicated above? (Select all that apply)*
  • What additional education or resources would help you overcome these barriers? (Select all that apply)*
  • Which patient care challenges related to HIV prevention remain difficult in your practice? (Select all that apply)*
  • What is your overall rating of this activity? *
    Rows
  • Please indicate your agreement with the following statements.*
    Rows

  • Please provide the following informaiton to receive your CME/CE Certificate.

  • Date
     - -
    2 digit month, 2 digit day, 4 digit year

  • The certificate emails auto-generated by this form are blocked by comcast.net email addresses. Please use an alternate email address if possible, or contact CEServices@academycme.org after submitting your form. **

  • IF Other          

  • PHARMACISTS: Please enter your NABP Number.*
  • PHARMACISTS: Please enter your MONTH and DAY of birth only (MMDD Format - NO YEAR).*
  • Amount of Time Spent in Activity/Number of Credits Claimed*

  • This educational activity was certified for a maximum of 1.0 AMA PRA Category 1 Credits(TM), 1.0 ANCC Contact Hours, 1.0 AAPA Category 1 CME credits, and 1.0 ACPE Contact Hours.

  • 1.25

  • 1.0

  • 0.75

  • 0.5

  • 0.0

  • Should be Empty: